Custom cancer vaccine trial tests new combo for deadly skin cancer
NCT ID NCT03929029
Summary
This early-stage study is testing the safety of a personalized vaccine made from a patient's own tumor combined with two immunotherapy drugs for advanced melanoma. The vaccine is designed to train the immune system to recognize and attack cancer cells. Researchers will enroll 11 patients to find the safest dose and see if this combination approach shows promise.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.